Seelos: Suicide study too small to meet endpoints

 

• SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality

• Robust Response and Remission Rates were observed using the Montgomery-Åsberg Depression Rating Scale (MADRS)

• Results demonstrate the therapeutic potential of SLS-002 to address imminent suicidality

• SLS-002 was well-tolerated, with no evidence of new or unique adverse events and there were no deaths reported in the study

• The Company will host a webcast with Dr. David V Sheehan, today, Wednesday, September 20th at 8:00 a.m. ET

Seelos will host a webcast today, Wednesday, September 20th, at 8 a.m. ET, to discuss the results. On the call from Seelos will be Raj Mehra, Ph.D., Chairman and CEO, and Tim Whitaker, M.D., Chief Medical Officer.

Additionally, David V. Sheehan, M.D., the Distinguished University Health Professor Emeritus at the University of South Florida College of Medicine, will be on the call as well to discuss this data.

Webcast for live and replay: https://lifescievents.com/event/seelos-2

A replay of the webcast will be available shortly following the presentation.

https://finance.yahoo.com/news/seelos-therapeutics-announces-top-line-110000268.html